Baseline mutations in the RTK pathway genes (NRAS, KRAS, PTPN11, KIT, NF1, BRAF, or FLT3) were enriched in patients with mutant IDH1 AML who did not achieve disease remission with ivosidenib treatment [148]. The gene discussed is FLT3; the disease is acute myeloid leukemia.